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Abstract. Approximately 40% of males with low Gleason 
grade clinically localized prostate cancer (PCa) at biopsy 
were finally diagnosed with high Gleason grade PCa at radical 
prostatectomy (RP). Therefore, a more reliable assessment of 
the Gleason grade prior to RP is required. Readily available 
modalities such as circulating biomarkers may be useful for 
this purpose. The aim of this study was to evaluate the ability 
of preoperative interleukin 6 (IL-6) and its soluble receptor 
(sIL-6R), as well as urokinase-type plasminogen activator 
(u-PA), its receptor (u-PAR) and the inhibitor (PAI-1) to predict 
Gleason score upgrading. A total of 51 PCa patients with 
biopsy Gleason score ≤7 were studied. IL‑6 and sIL‑6R, uPA, 
uPAR and PAI-1 preoperative serum levels were determined. 
Differences in the median and mean values of the preopera-
tive blood levels of all biomarkers between patients with and 
without Gleason score upgrading were tested. The prognostic 
performance of each biomarker was further assessed by 
means of receiver operating characteristic (ROC) curves. 
The results showed the sIL-6R and sIL-6R/IL-6 ratio median 
levels to be significantly higher in patients who had Gleason 
score upgrading from ≤7 at biopsy to >7 at RP (p=0.024 and 
p=0.011, respectively). The ROC curve revealed that sIL-6R 
and the sIL‑6R/IL‑6 ratio identified subjects at a high risk of 
upgrading [area under curve (AUC)=0.80 and AUC=0.83, 
respectively] with similar sensitivity and higher specificity for 
the ratio. The findings suggest that preoperative sIL‑6R and 
sIL-6R/IL-6 ratio determination in serum are useful as prog-
nostic biomarkers in PCa patients.
Introduction
Patients with clinically localized PCa are classified as low, 
intermediate and high risk, according to prostate‑specific 
antigen (PSA) levels, tumor clinical staging and Gleason score 
(GS). Patients with GS >7 belong to the high‑class risk cate-
gory (1,2). Treatment options depend on the recurrence risk. 
Although radical prostatectomy (RP) is recommended for the 
low to intermediate risk categories, a high-risk class category 
requires aggressive local radiation combined with 2‑3 years of 
androgen-deprivation therapy (ADT) (1,2).
GS upgrading from ≤6 at biopsy to ≥7 at RP has been 
reported to be approximately 40% (3,4). Thus factors predic-
tive of GS upgrading at RP are required. A promising modality 
may be represented by molecules involved in PCa progression, 
which are detectable in blood. These molecules include inter-
leukin 6 (IL-6) as well as its soluble receptor (sIL-6R) and 
urokinase-type plasminogen system members. IL-6 stimulates 
cell proliferation (5) and increases angiogenesis and invasion 
in tumor cells (6,7). The soluble form of the membrane IL-6 
receptor (mIL-6R) binds the cytokine, and their complex 
is capable of activating the transmembrane protein, gp130, 
which promotes signal transduction in cells that do not express 
mIL-6R (IL-6 trans-signaling) (8). Certain authors observed a 
strong association between circulating sIL-6R levels prior to 
prostatectomy and the higher probability of developing metas-
tases (9,10) and disease relapse (11).
The urokinase-type plasminogen system includes the 
activator (uPA), the receptor (uPAR) and the inhibitors (PAIs). 
uPA binds to its receptor uPAR, stimulating cleavage of plas-
minogen in plasmin and promoting cell motility, invasion, 
proliferation and survival in various human malignancies (12). 
The uPA system is negatively regulated by PAIs, which 
neutralize the proteolytic activity of uPA (13). The upregula-
tion of uPA correlates with the aggressive phenotype and poor 
prognosis of PCa (14-16).
This study evaluated the ability of preoperative blood levels 
of IL-6 and its soluble receptor (sIL-6R), as well as uPA, uPAR 
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and PAI-1, to predict GS upgrading from ≤7 at biopsy to >7 
at RP. This GS upgrading classification is significant to allow 
clinicians to select appropriate treatment at initial diagnosis.
Patients and methods
Patients. During a one‑year period, a total of 51 subjects with 
PCa, ranging from 51 to 75 years of age (median 64 years), 
were enrolled at our institution. Informed consent was obtained 
from the subjects. Inclusion criteria were: no evidence of active 
infection or inflammatory disease, no neo‑adjuvant androgen 
therapy, no 5α‑reductase inhibitor treatment, PSA ≤20 ng/ml, 
T‑clinical stage ≤2c (according to the 2009 TNM system). 
Between 12 and 18 needle biopsy cores were obtained under 
transrectal ultrasound (TRUS) guidance: 40 patients (74%) had 
12 cores obtained and 11 had 14‑18 cores in glands ≥50 cm3, 
including transition zone (TZ) cores. Primary and secondary 
GSs were assigned by a single pathologist. The prostatectomy 
specimens were processed according to the Stanford protocol 
and were also graded according to the Gleason system. GS 
upgrading was defined as a Gleason sum increase between 
biopsy and RP from ≤7 to >7.
Serum biomarkers. Preoperative serum samples were collected 
prior to digital rectal examination (DRE) and TRUS. Blood 
was collected into non-heparinized tubes and serum was sepa-
rated within 1 h of blood collection. The serum was stored at 
-80˚C and then thawed just prior to testing. Serum levels of 
PSA, free-PSA and IL-6 were measured using the Immulite 
2000 automated assay (DPC, Los Angeles, CA, USA). The 
concentrations of sIL-6R (R&D Systems, Minneapolis, MN, 
USA), uPA, uPAR and PAI‑1 (Assaypro, Winfield, MO, USA) 
in serum were determined according to the manufacturer's 
instructions using the ELISA test. Every sample was run in 
duplicate and the mean was used. The differences between the 
two measurements were minimal.
Data analysis and statistics. Data for continuous variables were 
the mean ± standard deviation (SD) and the median with the 
interquartile range. Data for categorical variables are presented 
as frequencies and percentages. Differences in median values 
of the preoperative blood levels of all of the biomarkers 
between patients with and without significant GS upgrading 
were tested using the exact Wilcoxon-Mann-Whitney test (or 
Wilcoxon rank-sum test). The difference in medians (95% CI) 
was based on the Hodges-Lehmann estimator. The prognostic 
performance of each biomarker was further assessed by 
means of ROC curves. Tests were two-sided and p<0.05 was 
considered to be statistically significant. Statistical analyses 
were performed using the R environment by the R Foundation, 
version 2.12.0.
Results
Patient characteristics are shown in Table I. Approximately 90% 
of patients had PSA <10 ng/ml and approximately 80% had % 
free PSA <15. The values of the analyzed biomarkers in samples 
classified on the basis of GS upgrading are shown in Table II.
GS upgrading was defined as a Gleason sum increase 
between biopsy and RP from ≤7 to >7, since this is important 
for the therapeutic strategy. On this basis, an upgrade was 
noted in 5 (10%) samples.
Median sIL‑6R values were found to be significantly 
higher in patients with GS upgrading (difference in medians, 
28.40 ng/ml; 95% CI, 5.60‑49.44; p=0.024). The association 
between sIL‑6R and GS upgrading became more significant 
by using the sIL‑6R/IL‑6 ratio (difference in medians, 7.77; 
95% CI, 1.72‑11.28; p=0.011). Sensitivity and specificity of 
sIL-6R and the sIL-6R/IL-6 ratio were explored by ROC 
curve analysis (Fig. 1). The results indicated an extremely 
good ability to predict the probability of biopsy Gleason sum 
upgrading of the two parameters (sIL‑6R: AUC=0.80; 95% 
CI, 0.63‑0.97; p=0.026. sIL‑6R/IL‑6 ratio: AUC=0.84; 95% 
CI, 0.69‑0.98; p=0.014). The optimal cut‑off point for sIL‑6R 
was 76.5 ng/ml, providing a sensitivity of 80% and a speci-
ficity of 76%, whereas for the sIL‑6R/IL‑6 ratio the optimal 
cut‑off point was 13.5 with comparable sensitivity (80%), but 
higher specificity (83%).
Discussion
The Gleason grading system remains one of the most powerful 
prognostic factors for prostate cancer, and plays a crucial role 
in the prediction of metastatic progression after RP (2,17). The 
National Comprehensive Cancer Network (NCCN) guidelines 
suggested that PCa diagnosed with a pathological Gleason 
Table I. Patient characteristics.
Characteristics Patients (%)
Clinical stage
  T1a 1 (2)
  T1c 22 (43)
  T2a 16 (31)
  T2b 2 (9)
  T2c 10 (18)
PSA (ng/ml)
  0‑4 27 (53)
  4.1‑10 19 (37)
  10.1-20 5 (9)
% free PSA
  1-10 25 (49)
  10.1‑15 17 (33)
  15.1-20 5 (9)
  >20 4 (7)
Biopsy Gleason score
  2‑4 3 (5)
  5‑6 32 (63)
  7 16 (31)
Radical prostatectomy
Gleason score
  5‑6 24 (47)
  7 22 (43)
  8-10 5 (10)
PSA, prostate‑specific antigen.
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sum >7 requires aggressive local radiation and no RP (1). 
Clinicians are in need of simple diagnostic modalities, avail-
able at initial diagnosis, which may be employed to estimate 
the clinical significance of cancer and guide their treatment 
decisions. Subsequently, we evaluated the ability of preopera-
tive blood levels of IL-6, sIL-6R , uPA, uPAR and PAI-1 to 
predict the magnitude of the risk of patients with a biopsy GS 
of ≤7 to harbor a higher‑grade cancer.
High sIL‑6R levels were found to be significantly 
associated with high-grade cancer diagnosed at RP and this 
relationship was strengthened by calculating the sIL-6R/IL-6 
ratio. This finding regarding the association between sIL‑6R 
circulating values and features of PCa aggressiveness and 
metastases is supported by the literature (9,10,18). Moreover, 
certain authors provided in vitro and in vivo evidence of the 
contribution of IL-6 to the development of androgen indepen-
dence (19-21). It was found that the serum concentration of 
sIL-6R is within a range higher than IL-6. This observation 
suggested that sIL-6R is crucial for the IL-6 pro-tumorigenic 
effect and IL-6 trans-signaling may be a relevant target in 
PCa treatment. This conclusion was strengthened by the 
ROC curve analysis outcomes indicating that the sIL-6R/IL-6 
ratio had a higher specificity in the prediction of a high RP 
Gleason sum compared to sIL-6R. Previous reports indicated 
that IL‑6 trans‑signaling may play a significant role in tumor 
progression by stabilizing IL-6 and enhancing IL-6-mediated 
signaling, which is capable of affecting the expression of genes 
involved in survival, proliferation, differentiation, osteogen-
esis/osteolysis, angiogenesis and immunomodulation (22-24). 
Jostock et al suggested that soluble gp130 (sgp130) is a 
natural specific inhibitor of IL‑6 trans‑signaling and may be 
used as a valuable therapeutic tool in disease states (25). In 
this regard, studies on the usefulness of sgp130 combined 
with IL-6 and sIL-6R blood levels to predict worse PCa prog-
nosis are noteworthy.
Nevertheless, this study is limited by the small number 
of patients included in the study population. Therefore, the 
Table II. Descriptive statistics of measured variables in serum of patients stratified by Gleason score upgrade (GSU). 
 Patients without GSU (n=46; 90%) Patients with GSU (n=5; 10%) Total (n=51)   p-valuea
 -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------
  Mean±SD Median (range) Mean±SD Median (range) Mean±SD Median (range) 
tPSA ng/ml 4.77±3.68 4.04 4.49±4.54 3.37 4.74±3.72 4.02 0.564
  (0.21‑17.9)  (0.93‑12.2)  (0.21‑17.9) 
fPSA ng/ml 0.52±0.44 0.45 0.53±0.46 0.41 0.52±0.44 0.44 0.848
  (0.07‑2.43)  (0.2‑1.33)  (0.07‑2.43) 
fPSA/tPSA 0.12±0.06 0.11 0.15±0.08 0.12 0.13±0.06 0.11 0.349
  (0.04‑0.33)  (0.1‑0.29)  (0.04‑0.33) 
uPA ng/ml 4.38±2.83 3.54 4.85±2.86 4.32 4.43±2.81 3.7 0.524
  (1-15)  (2-9)  (1-15) 
uPAR ng/ml 1.13±0.88 0.9 0.86±0.53 1.1 1.1±0.85 0.9 0.673
  (0-5.4)  (0.2-1.4)  (0-5.4) 
PAI‑1 ng/ml 41.09±17.92 40 47.07±17.25 47.07 41.67±17.78 40.44 0.468
  (13.2‑84)  (29.18‑73.07)  (13.2‑84) 
IL‑6 ng/ml 18.66±45.95 6.51 6.08±0.63 5.83 17.47±43.84 6.5 0.237
  (2.3‑281)  (5.5‑6.9)  (2.3‑281) 
sIL‑6R ng/ml 65.62±23.87 62.46 94.63±33.31 90.86 68.41±25.99 64.06 0.024
  (28.62‑133.7)  (62.06‑149.7)  (28.62‑149.7) 
sIL-6R/ IL-6 9.23±5.78 7.81 15.61±4.94 15.58 9.84±5.97 8.36 0.011
  (0‑30)  (9‑23)  (0‑30) 
aBased on the exact Wilcoxon-Mann-Whitney test (or Wilcoxon rank-sum test).
Figure 1. ROC analysis comparing sIL-6R (--) and sIL-6R/IL-6 ratio (–).
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findings may not be extended in clinical practice prior to 
further evaluation, ideally in a multicenter study on a larger 
population, in order to confirm the use of the sIL‑6R/IL‑6 
ratio as a routine marker in PCa patient management.
sIL‑6R may be a significant circulating biomarker 
employed to predict GS upgrading in patients with a biopsy 
GS ≤7. Moreover, this ability appears to be enhanced by 
calculating the sIL‑6R/IL‑6 ratio. These findings may provide 
an additional 'staging tool' for PCa patients, which may be of 
great significance in guiding clinicians' treatment choices, 
according to current guidelines.
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